Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 4
2017 4
2019 4
2020 2
2021 6
2022 3
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways.
López-Isac E, Acosta-Herrera M, Kerick M, Assassi S, Satpathy AT, Granja J, Mumbach MR, Beretta L, Simeón CP, Carreira P, Ortego-Centeno N, Castellvi I, Bossini-Castillo L, Carmona FD, Orozco G, Hunzelmann N, Distler JHW, Franke A, Lunardi C, Moroncini G, Gabrielli A, de Vries-Bouwstra J, Wijmenga C, Koeleman BPC, Nordin A, Padyukov L, Hoffmann-Vold AM, Lie B; European Scleroderma Group†; Proudman S, Stevens W, Nikpour M; Australian Scleroderma Interest Group (ASIG); Vyse T, Herrick AL, Worthington J, Denton CP, Allanore Y, Brown MA, Radstake TRDJ, Fonseca C, Chang HY, Mayes MD, Martin J. López-Isac E, et al. Nat Commun. 2019 Oct 31;10(1):4955. doi: 10.1038/s41467-019-12760-y. Nat Commun. 2019. PMID: 31672989 Free PMC article.
Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis.
Kerick M, Acosta-Herrera M, Simeón-Aznar CP, Callejas JL, Assassi S; International SSc Group; Proudman SM, Nikpour M; Australian Scleroderma Interest Group (ASIG); PRECISESADS Clinical Consortium; Hunzelmann N, Moroncini G, de Vries-Bouwstra JK, Orozco G, Barton A, Herrick AL, Terao C, Allanore Y, Fonseca C, Alarcón-Riquelme ME, Radstake TRDJ, Beretta L, Denton CP, Mayes MD, Martin J. Kerick M, et al. NPJ Genom Med. 2022 Oct 5;7(1):57. doi: 10.1038/s41525-022-00327-8. NPJ Genom Med. 2022. PMID: 36198672 Free PMC article.
Clinical characteristics and survival of pulmonary arterial hypertension with or without interstitial lung disease in systemic sclerosis.
Fairley JL, Hansen D, Ross L, Proudman S, Sahhar J, Ngian GS, Walker J, Host LV, Morrisroe K, Apostolopoulous D, Ferdowsi N, Wilson M, Tabesh M, Stevens W, Nikpour M; Australian Scleroderma Interest Group. Fairley JL, et al. Arthritis Res Ther. 2023 May 12;25(1):77. doi: 10.1186/s13075-023-03059-x. Arthritis Res Ther. 2023. PMID: 37173780 Free PMC article.
A Composite Serum Biomarker Index for the Diagnosis of Systemic Sclerosis-Associated Interstitial Lung Disease: A Multicenter, Observational Cohort Study.
Jee AS, Stewart I, Youssef P, Adelstein S, Lai D, Hua S, Stevens W, Proudman S, Ngian GS, Glaspole IN, Moodley YP, Bleasel JF, Macansh S, Nikpour M, Sahhar J, Corte TJ; Australian Scleroderma Cohort Study, Australian Scleroderma Interest Group, Australian Idiopathic Pulmonary Fibrosis Registry, and associated investigators. Jee AS, et al. Arthritis Rheumatol. 2023 Aug;75(8):1424-1433. doi: 10.1002/art.42491. Epub 2023 May 15. Arthritis Rheumatol. 2023. PMID: 36908055
Occupational silica exposure in an Australian systemic sclerosis cohort.
Patel S, Morrisroe K, Proudman S, Hansen D, Sahhar J, Sim MR, Ngian GS, Walker J, Strickland G, Wilson M, Ferdowsi N, Major G, Roddy J, Stevens W, Nikpour M; Australian Scleroderma Interest Group. Patel S, et al. Rheumatology (Oxford). 2020 Dec 1;59(12):3900-3905. doi: 10.1093/rheumatology/keaa446. Rheumatology (Oxford). 2020. PMID: 32911541
Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling.
Barbacki A, Baron M, Wang M, Zhang Y, Stevens W, Sahhar J, Proudman S, Nikpour M, Man A; Australian Scleroderma Interest Group and the Canadian Scleroderma Research Group. Barbacki A, et al. Arthritis Care Res (Hoboken). 2023 Mar;75(3):640-647. doi: 10.1002/acr.24873. Epub 2022 Nov 15. Arthritis Care Res (Hoboken). 2023. PMID: 35226416
Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis.
Ferdowsi N, Huq M, Stevens W, Hudson M, Wang M, Tay T, Burchell JL, Mancuso S, Rabusa C, Sundararajan V, Prior D, Proudman SM, Baron M, Nikpour M; Scleroderma Clinical Trials Consortium Damage Index Working Group, The Australian Scleroderma Interest Group, Canadian Scleroderma Research Group; Scleroderma Clinical Trials Consortium Damage Index Working Group, TheAustralian Scleroderma Interest Group, Canadian Scleroderma Research Group. Ferdowsi N, et al. Ann Rheum Dis. 2019 Jun;78(6):807-816. doi: 10.1136/annrheumdis-2018-214764. Epub 2019 Mar 30. Ann Rheum Dis. 2019. PMID: 30928903
Immunosuppression does not prevent severe gastrointestinal tract involvement in systemic sclerosis.
Richard N, Gyger G, Hoa S, Proudman S, Stevens W, Nikpour M, Wang M, Schnitzer ME, Baron M, Hudson M; Canadian Scleroderma Research Group (CSRG), Australian Scleroderma Interest Group (ASIG). Richard N, et al. Clin Exp Rheumatol. 2021 Jul-Aug;39 Suppl 131(4):142-148. doi: 10.55563/clinexprheumatol/7683pg. Epub 2021 Jun 9. Clin Exp Rheumatol. 2021. PMID: 34128797 Free article.
Clinical Features of Systemic Sclerosis-Mixed Connective Tissue Disease and Systemic Sclerosis Overlap Syndromes.
Fairley JL, Hansen D, Proudman S, Sahhar J, Ngian GS, Walker J, Strickland G, Wilson M, Morrisroe K, Ferdowsi N, Major G, Roddy J, Stevens W, Nikpour M; Australian Scleroderma Interest Group. Fairley JL, et al. Arthritis Care Res (Hoboken). 2021 May;73(5):732-741. doi: 10.1002/acr.24167. Epub 2021 Apr 3. Arthritis Care Res (Hoboken). 2021. PMID: 32058672
26 results